Content Navigation
( All
None )
| Target and Pathway |
Top |
| Target(s) |
DNA-dependent protein kinase catalytic (PRKDC) |
Target Info
|
Inhibitor |
[2] |
| References |
Top |
| REF 1 |
ClinicalTrials.gov (NCT03907969) A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.. U.S. National Institutes of Health.
|
| REF 2 |
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun. 2019 Nov 7;10(1):5065.
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.
